Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/29/2020 06/02/2020 06/03/2020 06/04/2020 06/05/2020 Date
83.03(c) 82.59(c) 82.48(c) 81.77(c) 83.04(c) Last
10 804 016 7 653 182 8 035 029 7 390 842 5 930 700 Volume
-0.42% -0.53% -0.13% -0.86% +1.55% Change
More quotes
Financials (USD)
Sales 2020 50 047 M - -
Net income 2020 9 407 M - -
Net Debt 2020 17 505 M - -
P/E ratio 2020 20,9x
Yield 2020 3,62%
Sales 2021 53 006 M - -
Net income 2021 11 187 M - -
Net Debt 2021 12 497 M - -
P/E ratio 2021 17,4x
Yield 2021 3,75%
Capitalization 190 B 190 B -
EV / Sales 2020 4,15x
EV / Sales 2021 3,82x
Nbr of Employees 109 000
Free-Float 84,4%
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (20.5%; Sandoz). Net sales... 
Sector
Pharmaceuticals
Calendar
06/12 | 02:00amPresentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
06/05NOVARTIS : PREVENT data show Cosentyx helps patients realize early and lasting r..
AQ
06/05Lonza picks Roche executive as CEO, ending year of turmoil at the top
RE
06/04GLOBAL MARKETS LIVE: LVMH buyer’s remorse, Amazon faces lawsuit…
06/03GENMAB A/S : - U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatu..
AQ
06/03NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
06/03NOVARTIS : Pliant Therapeutics Upsized IPO Priced at High End of Range
DJ
06/03NOVARTIS : FDA Extends Review of Novartis's Ofatumumab
DJ
06/02Softbank leads funding round in Brazilian data company Cortex
RE
06/01NOVARTIS : announces long-term, relapse-free survival benefit for high-risk, sta..
AQ
05/29NOVARTIS : data highlight benefit of early treatment initiation in patients with..
AQ
05/29GLOBAL MARKETS LIVE: Trump vs Twitter, Amazon hires, Cisco makes new purchase..
05/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
05/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
05/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
05/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
News in other languages on NOVARTIS AG
06/05Aktien Schweiz Schluss: US-Jobmarktdaten beflügeln vor dem Wochenende
06/05Bourse Zurich: les indices ont profité de la bonne surprise de l'emploi US
06/05ELON MUSK : UNTERNEHMEN vom 05.06.2020 - 15.15 Uhr
06/05NOVARTIS : PREVENT data show Cosentyx helps patients realize early and lasting r..
06/05Lonza holt sich den neuen Konzernchef bei Roche
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Stock Trading Strategies
NOVARTIS AG - 05/26
The calm spell can be taken advantage of to put on new positions
BUY
More Stock Trading Analysis
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 100,47 $
Last Close Price 86,26 $
Spread / Highest target 50,2%
Spread / Average Target 16,5%
Spread / Lowest Target -10,8%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-9.64%190 062
JOHNSON & JOHNSON0.98%388 076
ROCHE HOLDING AG5.78%293 869
MERCK & CO., INC.-9.55%207 633
PFIZER, INC.-8.14%199 918
ABBVIE INC.6.00%165 396